This paper reviews the cardiovascular implications of several major obesity medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), orlistat, naltrexone-bupropion, phentermine-topiramate, and setmelanotide. This evidence concerns the gene GLP1R and obesity disorder.